Tumor ablation market is anticipated to grow at a significant CAGR of 12.7% during the forecast period (2024-2031). The market growth is attributed to the increasing demand for minimally and non-invasive therapies, the growing adoption of advanced tumor ablation techniques, and the rising prevalence of cancer. According to the World Health Organization (WHO), in February 2024, there were an estimated 20 million new cancer cases and 9.7 million mortalities in 2022. The estimated number of people who were alive within 5 years following a cancer diagnosis was 53.5 million. About 1 in 5 people develop cancer in their lifetime, approximately 1 in 9 men and 1 in 12 women mortality occurs from the disease.

Market Dynamics

Increasing Demand for Radiofrequency Ablation (RFA) Devices 

Radiofrequency ablation (RFA) device uses rapidly alternating radiofrequency current to induce frictional heat around probes placed in tissue, producing cell death by coagulation necrosis. One of the most promising advancements in percutaneous microwave ablation is the triaxial antenna. This device consists of a coaxial monopole antenna placed through an introducer needle and is tunable to optimize its use in different tissues. RFA has the advantage of being a relatively low-risk minimally invasive procedure used in the treatment of focal liver tumors. 

Growing Laparoscopic Minimally Invasive Surgery

Minimally invasive surgery laparoscopic ablation is carried out with the use of thin instruments and a video camera. The laparoscopic tumor ablation involves removing tumors from a patient's liver, kidney, lungs, and bone. Using heat (RFA) and a clot (cryoablation), surgeons eliminate the aberrant tissue through the skin using tiny instruments. The minimally invasive operations are growing increasingly popular as a substitute for invasive therapies owing to their quicker procedures, less pain, shorter hospital stays, quicker recovery times, and reduced blood loss during treatment.

Market Segmentation

• Based on the technology, the market is segmented into radiofrequency ablation, microwave ablation, cryoablation, and percutaneous ethanol ablation.

• Based on the application, the market is segmented into liver cancer, lung cancer, breast cancer, prostate cancer, and others (kidney cancer).

• Based on the end-users, the market is segmented into hospitals, surgical clinics, and research institutions.

RFA is Projected to Hold the Largest Segment

The primary factors supporting the growth include efficiency and specificity in solid tumor ablation techniques for the liver, bone, and kidney. Furthermore, RFA treats numerous tumors concurrently, utilizing many electrodes positioned at different sites to improve procedural efficiency. Ablation of metastatic bone tumors is a minimally invasive method in which radiofrequency energy is delivered by probes to heat and destroy the tumor to prevent overheating, water is circulated to cool the probes near the active tip. For instance, in March 2024, Medtronic plc, in healthcare technology received US (FDA) 510(k) clearance for its OsteoCool 2.0 bone tumor ablation system for the treatment of painful bone metastases and benign bone tumors such as osteoid osteoma. An upgraded design of the OsteoCool radiofrequency ablation system brings several new advantages over the previous system. It allows the simultaneous use of four internally cooled probes, enabling physicians to ablate two vertebral bodies at once or create larger ablation zones in extra-spinal applications.

Breast Cancer Segment to Hold a Considerable Market Share

The high prevalence of breast cancer and positive results of tumor ablation for breast cancer treatment is a key contributors to the high share of this market segment. According to the National Center for Biotechnology Information (NCBI), in March 2023, Breast cancer (BC) is the most frequently diagnosed malignancy among women, accounting for 28.8% of all cancer diagnoses. In December 2022, Novian Health received Frost & Sullivan’s 2022 European New Product Innovation Award in the breast tumor ablation industry for its Novilase Breast Therapy system. Novilase is a thermal ablation device that uses laser heat to destroy tumor cells without lumpectomy surgery. The intended use is for the focal destruction of malignant and benign tumors of the breast.

Regional Outlook

Global tumor ablation market is further segmented based on geography including North America (the US, and Canada), Europe (the UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America). 

Growing Demand for Tumor Ablation in Asia-Pacific

• The regional growth is attributed to increasing awareness about cancer, early diagnostic techniques, and the easy availability of advanced, minimally invasive therapeutic options. According to the European Commission (EC), in October 2023, new cancer cases increased by 2.3 % compared to 2020, to reach 2.74 million in 2022. Similarly, cancer mortalities went up by 2.4 % compared to 2020. Breast cancer remains the most diagnosed cancer in the EU, with an estimated 380,000 cases (99.0% of these affecting women) which constitutes some 13.8% of all cancer diagnoses. This is followed by colorectal (356,000, 13.0% of all new cases), prostate (330,000, 12.1%), and lung cancer (319,000, 11.6%).

Global Tumor Ablation Market Growth by Region 2024-2031

North America Holds Major Market Share

North America holds a significant share owing to the presence of major tumor ablation companies such as Johnson & Johnson Services, Inc., Medtronic Plc, Olympus Corp., and others. The market growth is attributed to government assistance for high-quality medical treatment, parity in purchasing power, reimbursement accessibility, and increasing cancer incidence. In January 2024, Boston Scientific Corp. announced received US (FDA) approval for the FARAPULSE Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System is indicated for the isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal (i.e., intermittent) atrial fibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment.

Market Players Outlook

*Note: Major Players Sorted in No Particular Order.

The major companies serving the tumor ablation market include Boston Scientific Corp., Integra Lifesciences, Medtronic Plc, Smith & Nephew Plc, and Stryker Corp. among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers and acquisitions to stay competitive in the market. 

Recent Development

• In September 2022, Stryker Corp. announced that its OptaBlate bone tumor ablation system (OptaBlate) received 510(k) clearance from the US FDA. The addition of the OptaBlate technology to Stryker’s Interventional Spine (IVS) portfolio expands on its core competencies in vertebral augmentation and radiofrequency ablation and completes its portfolio of treatment options for metastatic vertebral body fractures.

The Report Covers

• Market value data analysis of 2023 and forecast to 2031.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the tumor ablation market. Based on the availability of data, information related to new products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.